Delisting Determination,The Nasdaq Stock Market, LLC,
September 26, 2016, EPIRUS Biopharmaceuticals, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove from
listing the common stock of EPIRUS Biopharmaceuticals, Inc.
(the Company), effective at the opening of the trading
session on October 6, 2016. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rules 5101, 5110(b), and IM-5101-1.
The Company was
notified of the Staffs determination on July 26, 2016.
The Company did not appeal the Staff determination to the
Hearings Panel, and the Staff determination to delist the
Company became final on August 4, 2016.